Searchable abstracts of presentations at key conferences in endocrinology

ea0081p189 | Reproductive and Developmental Endocrinology | ECE2022

Is there a link between polycystic ovary syndrome and transgenerational transmission of a reproductive and metabolic function in male offspring?

Risal Sanjiv , Li Congru , Luo Qing , Fornes Romina , Manti Maria , Lu Haojiang , Eriksson Gustaw , Ohlsson Claes , Lindgren Eva , Crisosto Nicolas , Maliqueo Manuel , Echiburu Barbara , Recabarren Sergio , Sir Petermann Teresa , Benrick Anna , Brusselaers Nele , Qiao Jie , Deng Qiaolin , Stener-Victorin Elisabet

Our previous study showed that polycystic ovary syndrome (PCOS)-like reproductive and metabolic phenotypes induced by maternal dihydrotestosterone (DHT)-exposure, can be passed on in mice from mothers (F0) to daughters (F1), granddaughters (F2), and even to great-granddaughters (F3). The female transmission is independent of diet-induced obesity and is mediated by transcriptional and mitochondrial perturbations of oocytes accompany. ...

ea0089b16 | Basic Science | NANETS2022

[212Pb]PSC-PEG2-TOC Therapy for NET Leads to Complete Responses in Mice Bearing SSTR2 Positive Tumors - Comparison to [177Lu]DOTATATE in a Preclinical Model

Schultz Michael K. , Liu Dijie , Li Mengshi , Cagle Brianna S. , Dai Zhiming , Lee Dongyoul , Orcutt Kelly , Sagastume Edwin , Baumhover Nicholas J. , Vance Ivy , Hedt Amos , Menda Yusuf , Johnson Frances L.

Background: Peptide-based targeted alpha-particle radiotherapy has emerged as a promising approach to cancer treatment. 203Pb/212Pb is the only elementally identical isotope pair for this application. Tyr3-Octreotide (TOC) peptide ligands targeting SSTR2 have been widely investigated preclinically and clinically. [177Lu]DOTATATE was approved by the US FDA to treat patients with gastroenteropancreatic neuroendocrine tumors. However, t...

ea0089c6 | Clinical – Chemo/SSA/Biologics | NANETS2022

An Open-Label, Phase 1b/2 study of Surufatinib in Combination with Tislelizumab in Patients with Advanced Neuroendocrine Tumors

Eads, MD Jennifer R. , Das, MD Satya , Li, MD Daneng , Mohamed, MD Amr , Tucci, MBS, CCRP Christopher , Nanda, MS Shivani , Kauh, MD, FACP John S. , Kania, MD, MBA Marek K. , Dasari, MD Arvind

Background: Surufatinib, an oral small molecule tyrosine kinase inhibitor, selectively inhibits vascular endothelial growth factor receptor 1, 2, and 3; fibroblast growth factor receptor 1; and colony-stimulating factor 1 receptor. Tislelizumab is a humanized immunoglobulin G4-variant anti-programmed cell death protein-1 monoclonal antibody. Combining surufatinib and tislelizumab may have synergistic effects, where inhibition of angiogenesis and stimulation of an immune respon...

ea0063oc4.5 | Thyroid 1 | ECE2019

A comprehensive assessment of the interplay between the thyroid function and the immune system: results from the Human Functional Genomics Project

Sloot Yvette , Jaeger Martin , Ter Horst Rob , Chu Xiaojing , Koenen Hans , Joosten Irma , Moorlag Simone , Mourits Vera , De Bree Charlotte , Koeken Valerie , van Herwaarden Antonius , Li Yang , Smit Jan , Netea Mihai , Netea-Maier Romana

Background: Accumulating evidence indicates the presence of bidirectional cross-talks between the endocrine and the immune system. However, no data are available on the influence of either the thyroid hormones or TSH within the normal range on the immune cell function in healthy humans.Aim: To comprehensively investigate the effects of the hypothalamic-pituitary-thyroid axis on the variation of immune responses in a cohort of healthy volunteers.<p cl...

ea0038ecp1.2 | (1) | SFEBES2015

Kisspeptin- A ‘key regulator’ of reproductive physiology, integrating limbic circuits with the regulation of reproductive hormones

Comninos Alexander , Anastasovska Jelena , Shah Amar , Wall Matthew , Jayasena Channa , Li Xiaofeng , Abbara Ali , Narayanaswamy Shaku , Nijher Gurjinder , Izzi-Engbeaya Chioma , Demetriou Lysia , Clarke Sophie , Ghatei Mohammad , Bell Jimmy , Matthews Paul , Bloom Stephen , O'Byrne Kevin , Dhillo Waljit

Kisspeptin is a recently identified reproductive hormone which serves as a crucial activator of the Hypothalamic–Pituitary–Gonadal (HPG) axis via stimulation of GnRH neurones. We have previously observed that a single kisspeptin injection increases LH pulsatility while twice daily kisspeptin injections can even advance the menstrual cycle. Furthermore, we have demonstrated that kisspeptin restores LH pulsatility in women with hypothalamic amenorrhoea and can potently...

ea0029oc12.4 | Obesity Clinical | ICEECE2012

Genetic susceptibility, birth weight and obesity risk in young chinese

Shi J. , Hong J. , Qi L. , Cui B. , Gu W. , Zhang Y. , Li L. , Xu M. , Wang L. , Zhai Y. , Miao L. , Wang R. , Bi Y. , Wang W. , Ning G.

Thus far, approximately 30 loci influencing body mass index (BMI) and the risk of obesity have been identified. In this study, we aimed to examine the individual and joint associations of 23 BMI-associated loci identified from recent genome-wide association studies in Caucasians with obesity risk in young Chinese. Birth weight reflects prenatal metabolic adaption and has been related to later-life obesity risk. We particularly assessed whether these genetic variants interacted...

ea0007p47 | Diabetes, metabolism and cardiovascular | BES2004

A novel non-steroidal inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 improves features of metabolic syndrome in murine disease models

Thieringer R , Balkovec J , Chen H , Frazier E , Le Grand C , Li Z , Metzger J , Mundt S , Nunes C , Strowski M , Olson S , Robertson N , Strack A , Schaeffer J , Wright S , Zhang B , Hermanowski-Votska A

Chronic exposure to elevated circulating glucocorticoids can lead to metabolic changes, which resemble those observed in Metabolic Syndrome. Features of the Metabolic Syndrome can be reversed by lowering systemic glucocorticoid levels or by treatment with a glucocorticoid receptor antagonist. At the intracellular level, exposure to glucocorticoids is regulated by two distinct 11beta-hydroxysteroid dehydrogenases, 11beta-HSD type 1 and type 2. 11beta-HSD1 predominantly acts as ...

ea0094op5.3 | Adrenal and Cardiovascular | SFEBES2023

Adrenal insufficiency can be associated with biallelic mutations in porphyria genes

Smith Chris , Al-Salihi Ahmed , Janecke Andreas , Steichen Elisabeth , Banka Siddharth , Jackson Adam , Darby Denise , Griffin Liezel , Stewart Sarah , Elsayed Solaf , Talbi Neila , Gouya Laurent , Chan Li , Metherell Louise

Adrenal insufficiency (AI) is life-threatening and can present alone or in combination with other co-morbidities. Acute porphyria attacks can also be serious, resulting in permanent disability or death and symptoms can be similar to AI. Previous literature describing hormonal perturbations in porphyria suggest an association between the two conditions. We were referred a family with 4 individuals with porphyria and AI, the clinical picture included global developmental delay, ...

ea0094cc1 | Section | SFEBES2023

Primary Unilateral Macronodular Adrenal Hyperplasia (PUMAH) With Concomitant Glucocorticoid And Androgen Excess due to KDM1A inactivation and constitute MC2R activation

Elhassan Yasir , Appenzeller Silke , Landwehr Laura , Popat Dillon , Gilligan Lorna , Goh Edwina , Diaz-Cano Salvador , Kircher Stefan , Gramlich Susanne , Sutcliffe Robert , Thangaratinam Shakila , Chan Li , Fassnacht Martin , Arlt Wiebke , Ronchi Cristina

Clinical vignette: We investigated a 33-year-old woman diagnosed during pregnancy with a 7cm unilateral adrenal mass associated with severe ACTH-independent glucocorticoid and androgen excess, a steroid phenotype usually indicative of adrenocortical carcinoma. Pregnancy had been achieved with in-vitro fertilisation on the assumption of underlying PCOS. Neonatal death occurred soon after emergency delivery due to foetal growth arrest at 26 weeks gestation. Hist...

ea0098c30 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Novel alternate (Alt) response criteria for early outcome prediction in pancreatic (P) neuroendocrine tumors (NETs): utilizing banked imaging and radiomics

Lareef Ishara , Vijayvergia Namrata , Handorf Elizabeth , Kunz Pamela L. , Alkim Emil , Burke Lauren M. , Catalano Paul , Graham Noah , Levin Laura , Li Weier , Meeker Caitlin , Rubin Daniel , Sridharan Anush , O'Dwyer Peter J. , Wong Terence Z. , Anaokar Jordan

Background: Evaluating treatment (Tx) Response in NETs using CT/MRI scans can be difficult. Previous studies, including the E2211, have shown improved progression-free survival (PFS) but no significant difference in Rp as measured by RECIST 1.1 (R1.1) criteria. Therefore, it is difficult to determine Tx effectiveness with short-term imaging, further complicated by differences in imaging protocols and inter-reader variability. Incorporating tumor density, using smaller threshol...